# Intellia Therapeutics Inc. (NTLA) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $12.74, market value $1.8 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Intellia Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 30.0×**. Each dollar of revenue is priced at 30.0×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 2.5×**. The shares trade at 2.5× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -19.5%** (5-yr avg -20.4%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -711.7%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -609.9%**. The company reported a net loss over the last twelve months.
- **Return on equity: -61.5%**. Return on equity is negative because earnings are negative.
- **Return on assets: -47.5%**. Each dollar of assets produces -47.5% of profit.

## Growth
- **Revenue growth (1 yr): 16.9%** (3-yr 9.1%/yr, 5-yr 3.1%/yr). Revenue grew 16.9% over the last year, against 3.1% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 27.4%**. Earnings per share rose 27.4%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Current ratio: 5.08** (quick 5.08). Current assets cover the next year's liabilities 5.08 times.
- **Altman Z-score: 6.35**. A Z-score of 6.35 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Intellia Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (17 analysts). 17 analysts cover Intellia Therapeutics Inc.; the consensus is buy, with an average price target of $23.94 (+88% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 9.6%** (YTD 41.7%, 3-mo -5.9%). The shares are up 9.6% over twelve months including dividends.
- **From 52-week high: -54.9%** (60.3% above the low). Trading 55% below its 52-week high, deep in a drawdown.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 52**. An RSI of 52 is neutral.
- **Beta (1 yr): 2.29** (volatility 99%). Beta of 2.29 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=NTLA · Page: https://foliofundamentals.com/stocks/ntla

Not investment advice.